Re-irradiation stereotactic body radiotherapy for spinal metastases: a multi-institutional outcome analysis

  • Ahmed Hashmi
    Department of Radiation Oncology, Sunnybrook Odette Cancer Centre, and
  • Matthias Guckenberger
    Department of Radiation Oncology, University of Wuerzburg, Germany;
  • Ron Kersh
    Department of Radiation Oncology, Riverside Medical Center, Newport News, Virginia;
  • Peter C. Gerszten
    Departments of Neurosurgery and
  • Frederick Mantel
    Department of Radiation Oncology, University of Wuerzburg, Germany;
  • Inga S. Grills
    Departments of Radiation Oncology and
  • John C. Flickinger
    Radiation Oncology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania;
  • John H. Shin
    Departments of Neurosurgery and
  • Daniel K. Fahim
    Neurosurgery, William Beaumont Hospital, Royal Oak, Michigan;
  • Brian Winey
    Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts;
  • Kevin Oh
    Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts;
  • B. C. John Cho
    Department of Radiation Oncology, Princess Margaret Cancer Center, University of Toronto, Ontario, Canada;
  • Daniel Létourneau
    Department of Radiation Oncology, Princess Margaret Cancer Center, University of Toronto, Ontario, Canada;
  • Jason Sheehan
    Department of Neurosurgery, University of Virginia Health System, Charlottesville, Virginia; and
  • Arjun Sahgal
    Department of Radiation Oncology, Sunnybrook Odette Cancer Centre, and

説明

<jats:sec> <jats:title>OBJECTIVE</jats:title> <jats:p>This study is a multi-institutional pooled analysis specific to imaging-based local control of spinal metastases in patients previously treated with conventional external beam radiation therapy (cEBRT) and then treated with re-irradiation stereotactic body radiotherapy (SBRT) to the spine as salvage therapy, the largest such study to date.</jats:p></jats:sec> <jats:sec> <jats:title>METHODS</jats:title> <jats:p>The authors reviewed cases involving 215 patients with 247 spinal target volumes treated at 7 institutions. Overall survival was calculated on a patient basis, while local control was calculated based on the spinal target volume treated, both using the Kaplan-Meier method. Local control was defined as imaging-based progression within the SBRT target volume. Equivalent dose in 2-Gy fractions (EQD2) was calculated for the cEBRT and SBRT course using an α/β of 10 for tumor and 2 for both spinal cord and cauda equina.</jats:p></jats:sec> <jats:sec> <jats:title>RESULTS</jats:title> <jats:p>The median total dose/number of fractions of the initial cEBRT was 30 Gy/10. The median SBRT total dose and number of fractions were 18 Gy and 1, respectively. Sixty percent of spinal target volumes were treated with single-fraction SBRT (median, 16.6 Gy and EQD2/10 = 36.8 Gy), and 40% with multiple-fraction SBRT (median 24 Gy in 3 fractions, EQD2/10 = 36 Gy). The median time interval from cEBRT to re-irradiation SBRT was 13.5 months, and the median duration of patient follow-up was 8.1 months. Kaplan-Meier estimates of 6- and 12-month overall survival rates were 64% and 48%, respectively; 13% of patients suffered a local failure, and the 6- and 12-month local control rates were 93% and 83%, respectively. Multivariate analysis identified Karnofsky Performance Status (KPS) < 70 as a significant prognostic factor for worse overall survival, and single-fraction SBRT as a significant predictive factor for better local control. There were no cases of radiation myelopathy, and the vertebral compression fracture rate was 4.5%.</jats:p></jats:sec> <jats:sec> <jats:title>CONCLUSIONS</jats:title> <jats:p>Re-irradiation spine SBRT is effective in yielding imaging-based local control with a clinically acceptable safety profile. A randomized trial would be required to determine the optimal fractionation.</jats:p></jats:sec>

収録刊行物

被引用文献 (2)*注記

もっと見る

問題の指摘

ページトップへ